drugset / Trial / NCT01250197

Formulation Comparison in Normal Volunteers

NCT01250197

Phase 1 Completed 18 enrolled Aerie Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days. Subjects will undergo a minimum 7-day washout, and then receive the alternate treatment for 8 days.

Timeline

Start
2010-11
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VEROSUDIL Small molecule 0.5 % Other

Indications

No indication recorded.